Soliris Prevents aHUS Recurrence in COVID-19 Patient in Case Study

Soliris Prevents aHUS Recurrence in COVID-19 Patient in Case Study

295527

Soliris Prevents aHUS Recurrence in COVID-19 Patient in Case Study

Treatment with Soliris (eculizumab) successfully prevented the recurrence of atypical hemolytic uremic syndrome (aHUS) in a 64-year-old woman who had received a kidney transplant, without compromising her recovery from COVID-19, a case study reports. The study, “COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report,” was published in the Journal of Nephrology. The patient was hospitalized at Strasbourg University Hospital, in France, in April 2020 after developing…

You must be logged in to read/download the full post.